Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Vaccines

an image of the vaccines

Demand for vaccines is on the rise worldwide, and Meiji is responding on several fronts. As well as our approved influenza, hepatitis and Japanese encephalitis vaccines, we continue to develop new vaccines for emerging threats such as coronaviruses and Dengue fever. We also manufacture combined vaccines and single-supply products for which no alternative products are available.

Our response to COVID-19

The Meiji Group is responding to COVID-19 on multiple fronts which include supplying antigen test kits and developing inactivated vaccines and therapeutic agents. Our inactivated vaccine KD-414, currently in development, utilizes knowledge we have accumulated over many years in the vaccine field. We started clinical trials in March 2021, and obtained results in September that showed a certain level of efficacy and a high level of safety. We are now expediting the supply of this vaccine by bringing forward the target date for commercial release. Read more about our ongoing efforts at the link below.

Countermeasures against Emerging and Re-emerging Infectious Diseases (PDF: 401KB)

Areas of Expertise

For more detailed information on all the products above, please visit the KM Biologics website.

VISIT SITE

  • an photo of a female researcher conducting an experiment
  • Infectious Disease Control is a National Security Issue

    Dengue fever is a mosquito-borne viral infection that can be fatal. Half the world's population is at risk, mainly in tropical and subtropical zones. Meiji Group company KM Biologics is developing a Dengue vaccine that has passed Phase I clinical trials. Unlike existing vaccines, the antibody is proving 100% effective at neutralizing all four Dengue serotypes with a single dose. The company is preparing for Phase II trials.